Torsdag 2 April | 00:51:29 Europe / Stockholm

Prenumeration

Kalender

Est. tid*
2026-11-20 07:00 Kvartalsrapport 2026-Q3
2026-08-21 07:00 Kvartalsrapport 2026-Q2
2026-05-25 N/A X-dag ordinarie utdelning PAX 0.00 SEK
2026-05-22 N/A Årsstämma
2026-05-21 07:00 Kvartalsrapport 2026-Q1
2026-02-27 - Bokslutskommuniké 2025
2025-11-14 - Kvartalsrapport 2025-Q3
2025-08-20 - Kvartalsrapport 2025-Q2
2025-05-19 - X-dag ordinarie utdelning PAX 0.00 SEK
2025-05-16 - Årsstämma
2025-05-16 - Kvartalsrapport 2025-Q1
2025-04-08 - Extra Bolagsstämma 2025
2025-02-21 - Bokslutskommuniké 2024
2024-11-15 - Kvartalsrapport 2024-Q3
2024-08-21 - Kvartalsrapport 2024-Q2
2024-05-24 - X-dag ordinarie utdelning PAX 0.00 SEK
2024-05-23 - Årsstämma
2024-05-23 - Kvartalsrapport 2024-Q1
2024-02-23 - Bokslutskommuniké 2023
2023-11-17 - Kvartalsrapport 2023-Q3
2023-08-24 - Kvartalsrapport 2023-Q2
2023-05-25 - X-dag ordinarie utdelning PAX 0.00 SEK
2023-05-24 - Årsstämma
2023-05-24 - Kvartalsrapport 2023-Q1
2023-02-24 - Bokslutskommuniké 2022
2022-11-18 - Kvartalsrapport 2022-Q3
2022-08-24 - Kvartalsrapport 2022-Q2
2022-05-27 - X-dag ordinarie utdelning PAX 0.00 SEK
2022-05-25 - Årsstämma
2022-05-25 - Kvartalsrapport 2022-Q1
2022-02-25 - Bokslutskommuniké 2021
2021-11-19 - Kvartalsrapport 2021-Q3
2021-08-27 - Kvartalsrapport 2021-Q2
2021-05-27 - X-dag ordinarie utdelning PAX 0.00 SEK
2021-05-26 - Årsstämma
2021-05-26 - Kvartalsrapport 2021-Q1
2021-02-26 - Bokslutskommuniké 2020
2020-11-20 - Kvartalsrapport 2020-Q3
2020-08-27 - Kvartalsrapport 2020-Q2
2020-05-28 - X-dag ordinarie utdelning PAX 0.00 SEK
2020-05-27 - Årsstämma
2020-05-27 - Kvartalsrapport 2020-Q1
2020-02-21 - Bokslutskommuniké 2019
2019-11-21 - Kvartalsrapport 2019-Q3
2019-08-29 - Kvartalsrapport 2019-Q2
2019-05-24 - X-dag ordinarie utdelning PAX 0.00 SEK
2019-05-23 - Årsstämma
2019-05-23 - Kvartalsrapport 2019-Q1
2019-02-27 - Bokslutskommuniké 2018
2018-11-22 - Kvartalsrapport 2018-Q3
2018-08-30 - Kvartalsrapport 2018-Q2
2018-05-25 - X-dag ordinarie utdelning PAX 0.00 SEK
2018-05-24 - Årsstämma
2018-05-24 - Kvartalsrapport 2018-Q1

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Paxman är verksamt inom skalpkylning, som används för patienter som behandlas för cytostatika. Bolagets produkt Paxman Scalp Cooler används för att minimera håravfallet hos patienten under behandlingens gång. Scalp Coolern är en fristående, mobil och eldriven kylenhet som kyler ner patientens hårbotten via en kylmössa. Paxman grundades 1996 och har sitt huvudkontor i Karlshamn.

Intresserad av bolagets nyckeltal?

Analysera bolaget i Börsdata!

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

2019-05-13 10:58:00

PAXMAN announces that the company now has installed or signed delivery agreements for just over 500 scalp cooling systems preventing hair loss in connection with chemotherapy in the USA, only two years after receiving FDA approval. The company is now actively supporting large-scale coverage and reimbursement for the treatment.

The latest installations in the USA include additional scalp cooling systems at the Mayo Clinc locations in Minnesota, Arizona, Florida and Wisconsin, and also at Memorial Sloan Kettering and Dana-Farber Cancer Institute. PAXMAN now has systems installed, or on their way to, 259 locations in 37 states.

“It is truly inspiring to be able to contribute to an improved quality of life and an increased level of control for so many patients in the USA, together with pre-eminent hospitals and cancer centres. We are now hoping that scalp cooling will become available regardless of the patient’s financial situation, and there are clear signs that things are moving in the right direction,” says PAXMAN’s CEO Richard Paxman.

An important step towards insurance coverage was taken in March, 2019, when the National Comprehensive Cancer Network® (NCCN®) included scalp cooling as a recommended category 2A treatment to prevent hair loss in its guidelines for treatment of invasive breast cancer. Additionally, it was announced on May 10th, 2019 that the House of Representatives in the state of Texas passed a bill (Texas H.B. 3984) that will make it mandatory for health care programs to cover scalp cooling costs for cancer patients. The next step is a voting in the Texas Senate, and finally the bill needs to be signed or allowed by the governor. PAXMAN has over 75 scalp cooling systems installed in Texas, with additional systems to be delivered. A positive outcome for this bill would send a powerful message to other states in the USA to implement similar legislation.

For more information on the legislation process in Texas, see https://house.texas.gov/about-us/bill/